Fig. 4: Attenuated response to SARS-CoV-2 infection in ChAdOx1 nCoV-19 vaccinees. | Nature Communications

Fig. 4: Attenuated response to SARS-CoV-2 infection in ChAdOx1 nCoV-19 vaccinees.

From: Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease

Fig. 4

a Volcano plot comparing next-gen RNA-seq blood transcriptome at CT in NAAT+ve (placebo vaccine) with baseline samples. Blue = downregulated at CT, red = upregulated at CT. b Agreement plot of differentially expressed genes at CT in NAAT+ve individuals in Placebo (x-axis) and ChAdOx1 nCoV-19 (y-axis) vaccinees compared with baseline. c Volcano plot comparing the next-gen RNA-seq blood transcriptome at COVID-19 onset in ChAdOx1 nCoV-19 vaccinees compared with placebo vaccinees. d Agreement plot of small RNA-seq differentially expressed genes at CT in NAAT+ve individuals in Placebo (x-axis) and ChAdOx1 nCoV-19 (y-axis) vaccinees compared with baseline. Coloured features differentially expressed in placebo arm (FDR < 0.05). e Boxplots of sRNA features differentially expressed (FDR < 0.05) between baseline and CT in the placebo vaccine group. Y-axis shows unadjusted p values. f Volcano plot comparing the small RNA-seq blood transcriptome at COVID-19 onset (NAAT +ve CT) in ChAdOx1 nCoV-19 vaccinees compared with placebo vaccinees. Red = higher in placebo group. g Serum cytokine levels measured at D0 (paired samples NAAT+ve ChAdOx1 nCoV-19 n = 5, NAAT+ve placebo n = 7) and symptom onset in Placebo (NAAT-ve n = 9, NAAT+ve n = 9) and ChAdOx1 nCoV-19 (NAAT-ve n = 8, NAAT+ve n = 7) vaccinees. Dashed line represents limit of detection. P values were derived from two-sided unpaired Wilcoxon tests. h Volcano plot comparing the 3rd gen ONT RNA-seq blood transcriptome COVID-19 onset (NAAT+ve CT) in ChAdOx1 nCoV-19 vaccinated participants compared with placebo vaccinees; 45,231 transcripts included in total. i MX1 ENST00000288383 transcript (MX1-201 isoform) expression across the study groups. Group sizes: D0 n = 10, CT NAAT-ve n = 13, CT NAAT+ve ChAdOx1 nCoV-19 n = 7, CT NAAT+ve placebo n = 9. Statistics: Unless otherwise stated above, differential gene expression analyses were performed using a two-sided moderated t test. Multiple testing correction applied to all differential expression analyses using the Benjamini-Hochberg method with an FDR < 0.05 deemed significant; *=FDR < 0.05, **=FDR < 0.01. Box plots: the centre line denotes the median value, the box contains the 25th (Q1) to 75th (Q3) percentiles of dataset. Whiskers mark the Q1 – 1.5*IQR and Q3 + 1.5*IQR. Source data are provided as a Source Data file.

Back to article page